Cover Image
市場調查報告書

PharmaPoint:腦膜炎疫苗 - 全球醫藥品的預測與市場分析

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 289835
出版日期 內容資訊 英文 424 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:腦膜炎疫苗 - 全球醫藥品的預測與市場分析 PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年05月24日 內容資訊: 英文 424 Pages
簡介

本報告提供全球腦膜炎病毒市場現況與未來展望相關分析,疾病概要和今後的流行病學的預測,主要國家的預防體性,主要企業簡介代表性產品,市場未滿足需求與未來性的機會,現在臨床實驗中的開發中產品的資訊,今後的市場規模及影響要素等調查。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 簡介
  • 病因與病理學
  • 症狀
  • 預後

第4章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本、巴西
  • 預測手法
  • 腦膜炎性疾病的流行病學的預測(今後11年份)
  • 議論

第5章 疾病的管理

  • 腦膜炎的預防政策
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 巴西

第6章 競爭環境

  • 概要
  • 產品簡介 - MenACWY疫苗
    • Menactra
    • Menveo
    • Nimenrix
  • 產品簡介 - MenB疫苗
    • Bexsero
    • Trumenba
  • 產品簡介 - MenC疫苗
    • NeisVac-C
    • Menjugate
    • Menitorix
  • 其他腦膜炎疫苗

第7章 未滿足需求與市場機會

  • 概要
  • 一般的腦膜炎疫苗的安全性和效果
  • 對侵入性腦膜炎的長期預防性
  • 臨床實驗設計的改善
  • 成本效率高的疫苗
  • 孕婦用腦膜炎疫苗
  • 嬰幼兒期的疫苗接種的減少
  • 強化一般教育和認識

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖與未來趨勢
  • 臨床實驗中有前途的疫苗
  • 臨床實驗的初期階段有潛力的疫苗

第9章 現在、未來市場參與企業

  • 概要
  • 企業策略概要
  • 企業簡介
    • GlaxoSmithKline
    • Sanofi
    • Pfizer

第10章 市場預測

  • 全球市場
    • 市場預測
    • 市場促進、阻礙因素:全球的課題
  • 美國
  • 歐洲5個國家
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 巴西

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC115PIDR

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
  • What will be the effect of recent and upcoming changes in national immunization schedules?
  • How will the new first-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
  • Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?

Key Findings

  • GlobalData projects the meningococcal vaccine market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
  • With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.
  • GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

  • Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.
  • Topline meningococcal vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global meningococcal vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Introduction
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and morbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan and Brazil
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used Tables
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for IMD (2015-2025)
    • 4.5.1. All IMD Combined
    • 4.5.2. Laboratory-Confirmed Incident Cases of Serogroup B IMD
    • 4.5.3. Laboratory-Confirmed Incident Cases of Serogroup C IMD
    • 4.5.4. Laboratory-Confirmed Incident Cases of Serogroup Y IMD
    • 4.5.5. Laboratory-Confirmed Incident Cases of Other Serogroup IMD
    • 4.5.6. Distribution of Serogroups
    • 4.5.7. US College Freshmen
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Meningococcal Immunization Policy
    • 5.1.1. Routine Immunization Recommendations and Most Frequently Administered Meningococcal Vaccines
  • 5.2. US
    • 5.2.1. Immunization Recommendations
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Immunization Recommendations
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Immunization Recommendations
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Immunization Recommendations
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Immunization Recommendations
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Immunization Recommendations
    • 5.7.2. Clinical Practice
  • 5.8. Japan
  • 5.9. Brazil
    • 5.9.1. Immunization Recommendations
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - MenACWY Vaccines
    • 6.2.1. Menactra
    • 6.2.2. Menveo
    • 6.2.3. Nimenrix
  • 6.3. Product Profiles - MenB Vaccines
    • 6.3.1. Bexsero
    • 6.3.2. Trumenba
  • 6.4. Product Profiles - MenC Vaccines
    • 6.4.1. NeisVac-C
    • 6.4.2. Menjugate
    • 6.4.3. Menitorix
  • 6.5. Other Meningococcal Vaccines
    • 6.5.1. Overview

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. A Safe and Effective Universal Meningococcal Vaccine
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Long-Term Protection Against Invasive Meningococcal Disease
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Improvements in Clinical Trial Design
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Vaccine Cost Effectiveness
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. A Prenatal Meningococcal Vaccine
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Reducing Vaccination Frequency in Infants
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Enhanced Education and Awareness of the General Population
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping and Future Trends
    • 8.2.1. Clinical Trials by Status
    • 8.2.2. Clinical Trials by Pipeline Vaccine
    • 8.2.3. Future Clinical Trial Design Considerations
  • 8.3. Promising Vaccines in Clinical Development
    • 8.3.1. MenABCWY
    • 8.3.2. Men Quad TT
    • 8.3.3. Brazil MenC Vaccine
  • 8.4. Promising Early-Stage Pipeline Products

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. GlaxoSmithKline
    • 9.3.2. Sanofi
    • 9.3.3. Pfizer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. 5EU
    • 10.3.2. France
    • 10.3.3. Germany
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. UK
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Brazil
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Vaccine Coverage
    • 11.4.2. Vaccine Approval vs. Routine Schedule Inclusion
    • 11.4.3. Vaccines Included
    • 11.4.4. Key Launch Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Vaccine Assumptions
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Managing Epidemiologist
    • 11.7.5. Global Director of Therapy Analysis and Epidemiology
    • 11.7.6. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Meningococcal Disease
  • Table 2: Risk Factors and Comorbidities for IMD
  • Table 3: 8MM, Sources of Laboratory-Confirmed IMD Incidence
  • Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence
  • Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence
  • Table 6: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence
  • Table 7: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W, X, and All Others)
  • Table 8: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W IMD Incidence
  • Table 9: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence
  • Table 10: College Freshmen Residing in Campus Accommodation
  • Table 11: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 12: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 13: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 14: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015
  • Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 17: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 18: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 19: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 20: National Immunization Recommendation Agencies, 2016
  • Table 21: National Immunization Recommendations for Meningococcal Vaccines, 2016
  • Table 22: Most Frequently Administered Meningococcal Vaccines in the Global Markets, 2015
  • Table 23: Country Profile - US
  • Table 24: Country Profile - France
  • Table 25: Country Profile - Germany
  • Table 26: Country Profile - Italy
  • Table 27: Country Profile - Spain
  • Table 28: Country Profile - UK
  • Table 29: Country Profile - Japan
  • Table 30: Country Profile - Brazil
  • Table 31: Leading Vaccines Against Meningococcal Disease, 2015
  • Table 32: Product Profile - Menactra
  • Table 33: Efficacy of Menactra for Individuals Receiving Either One- or Two-Dose Regimens
  • Table 34: Safety of Menactra for Individuals Receiving One Dose of Menactra
  • Table 35: Menactra SWOT Analysis, 2016
  • Table 36: Global Sales Forecast ($m) for Menactra, 2015-2025
  • Table 37: Product Profile - Menveo
  • Table 38: Efficacy of Menveo
  • Table 39: Safety of Menveo
  • Table 40: Menveo SWOT Analysis, 2016
  • Table 41: Global Sales Forecasts ($m) for Menveo, 2015-2025
  • Table 42: Product Profile - Nimenrix
  • Table 43: Efficacy of Nimenrix
  • Table 44: Safety of Nimenrix
  • Table 45: Nimenrix SWOT Analysis, 2016
  • Table 46: Global Sales Forecast ($m) for Nimenrix, 2015-2025
  • Table 47: Product Profile - Bexsero
  • Table 48: Efficacy of Bexsero
  • Table 49: Safety of Bexsero
  • Table 50: Bexsero SWOT Analysis, 2016
  • Table 51: Global Sales Forecasts ($m) for Bexsero, 2015-2025
  • Table 52: Product Profile - Trumenba
  • Table 53: Efficacy of Trumenba
  • Table 54: Safety of Trumenba
  • Table 55: Trumenba SWOT Analysis, 2016
  • Table 56: Global Sales Forecasts ($m) for Trumenba, 2015-2025
  • Table 57: Product Profile - NeisVac-C
  • Table 58: Efficacy of NeisVac-C
  • Table 59: Safety of NeisVac-C
  • Table 60: NeisVac-C SWOT Analysis, 2016
  • Table 61: Global Sales Forecasts ($m) for NeisVac-C, 2015-2025
  • Table 62: Product Profile - Menjugate
  • Table 63: Efficacy of Menjugate
  • Table 64: Safety of Menjugate
  • Table 65: Menjugate SWOT Analysis, 2016
  • Table 66: Global Sales Forecasts ($m) for Menjugate, 2015-2025
  • Table 67: Product Profile - Menitorix
  • Table 68: Efficacy of Menitorix
  • Table 69: Safety of Menitorix
  • Table 70: Menitorix SWOT Analysis, 2016
  • Table 71: Global Sales Forecasts ($m) for Menitorix, 2015-2025
  • Table 72: Other Meningococcal Vaccines
  • Table 73: Unmet Needs and Opportunities for Meningococcal Vaccines
  • Table 74: Product Profile - MenABCWY
  • Table 75: Immunogenicity of MenABCWY
  • Table 76: MenABCWY SWOT Analysis, 2016
  • Table 77: Global Sales Forecast ($m) for MenABCWY, 2015-2025
  • Table 78: Product Profile - Men Quad TT
  • Table 79: Men Quad TT SWOT Analysis, 2016
  • Table 80: Global Sales Forecasts ($m) for Men Quad TT, 2015-2025
  • Table 81: Product Profile - Brazil's MenC
  • Table 82: Brazil MenC SWOT Analysis, 2016
  • Table 83: Global Sales Forecast ($m) for Brazil's MenC, 2015-2025
  • Table 84: Important Meningococcal Vaccines in Development, 2016
  • Table 85: Key Companies in the Meningococcal Vaccine Market in the 8MM, 2016
  • Table 86: GSK's Meningococcal Vaccines Portfolio Assessment, 2016
  • Table 87: GSK SWOT Analysis in Meningococcal Vaccines, 2016
  • Table 88: Sanofi's Meningococcal Vaccines Portfolio Assessment, 2016
  • Table 89: Sanofi SWOT Analysis in Meningococcal Vaccines, 2016
  • Table 90: Pfizer's Meningococcal Vaccines Portfolio Assessment, 2016
  • Table 91: Pfizer SWOT Analysis in Meningococcal Vaccines, 2016
  • Table 92: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2015-2025
  • Table 93: 8MM Meningococcal Vaccines Market - Drivers and Barriers, 2015-2025
  • Table 94: US Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025
  • Table 95: Key Events Impacting Sales for Meningococcal Disease in the US, 2015?2025
  • Table 96: US Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 97: 5EU Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025
  • Table 98: 5EU Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 99: France Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025
  • Table 100: Key Events Impacting Sales for Meningococcal Vaccines in France, 2015?2025
  • Table 101: France Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 102: Sales Forecast ($m) for Meningococcal Vaccines in Germany, 2015?2025
  • Table 103: Key Events Impacting Sales for Meningococcal Disease in Germany, 2015?2025
  • Table 104: Germany Meningococcal Vaccines market - Drivers and Barriers, 2015?2025
  • Table 105: Italy Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025
  • Table 106: Key Events Impacting Sales for Meningococcal Disease in Italy, 2015?2025
  • Table 107: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 108: Spain Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025
  • Table 109: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2015?2025
  • Table 110: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 111: UK Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025
  • Table 112: Key Events Impacting Sales for Meningococcal Disease in the UK, 2015?2025
  • Table 113: UK Meningococcal Vaccines market - Drivers and Barriers, 2015?2025
  • Table 114: Japan Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025
  • Table 115: Key Events Impacting Sales for Meningococcal Vaccines in Japan, 2015?2025
  • Table 116: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 117: Brazil Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025
  • Table 118: Key Events Impacting Sales for Meningococcal Disease in Brazil, 2015?2025
  • Table 119: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 120: Key Launch Dates
  • Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Membrane Structure of N. meningitidis
  • Figure 2: Genetic Clusters for Polysaccharide Capsules
  • Figure 3: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014
  • Figure 4: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 5: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015
  • Figure 6: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015
  • Figure 7: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015
  • Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 10: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 11: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 12: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015
  • Figure 13: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025
  • Figure 14: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 15: National Immunization Schedule for Meningococcal Vaccines across the 8MM
  • Figure 16: Meningococcal Vaccines - Key Clinical Trial Landscape, 2016
  • Figure 17: Meningococcal Vaccines - Phase II/III Pipeline, 2016
  • Figure 18: Competitive Assessment of Late-Stage Pipeline Meningococcal Vaccines, 2015-2025
  • Figure 19: Clinical and Commercial Positioning of MenABCWY
  • Figure 20: Clinical and Commercial Positioning of Men Quad TT
  • Figure 21: Clinical and Commercial Positioning of Brazil's MenC
  • Figure 22: Global Sales of Branded Vaccines for Meningococcal Disease by Company, 2015-2025
  • Figure 23: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2015-2025
  • Figure 24: Annual Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 25: Global Sales for Meningococcal Vaccines by Region, 2015 and 2025
  • Figure 26: US Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 27: Sales of Meningococcal Vaccines by Type of Vaccine in the 5EU in 2015 and 2025
  • Figure 28: France Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 29: Germany Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 30: Italy Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 31: Spain Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 32: UK Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 33: Japan Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
  • Figure 34: Brazil Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Back to Top